Korean J Gastroenterol.  2016 Jun;67(6):313-317. 10.4166/kjg.2016.67.6.313.

Non-Helicobacter pylori, Non-nonsteroidal Anti-inflammatory Drug Peptic Ulcer Disease

• Chang YW

• KMID: 2307757
• DOI: http://doi.org/10.4166/kjg.2016.67.6.313

Abstract

Non-Helicobacter pylori, non-NSAID peptic ulcer disease (PUD), termed idiopathic PUD, is increasing in Korea. Diagnosis is based on exclusion of common causes such as H. pylori infection, infection with other pathogens, surreptitious ulcerogenic drugs, malignancy, and uncommon systemic diseases with upper gastrointestinal manifestations. The clinical course of idiopathic PUD is delayed ulcer healing, higher recurrence, higher re-bleeding after initial ulcer healing, and higher mortality than the other types of PUD. Genetic predisposition, older age, chronic mesenteric ischemia, cigarette smoking, concomitant systemic diseases, and psychological stress are considered risk factors for idiopathic PUD. Diagnosis of idiopathic PUD should systematically explore all possible causes. Management of this disease is to treat underlying disease followed by regular endoscopic surveillance to confirm ulcer healing. Continuous proton pump inhibitor therapy is an option for patients who respond poorly to the standard ulcer regimen.

Keyword

Non-Helicobacter pylori; Non-nonsteroidal anti-inflammatory agents; Idiopathic peptic ulcer; Proton pump inhibitors

MeSH Terms

Diagnosis
Genetic Predisposition to Disease
Humans
Korea
Mesenteric Ischemia
Mortality
Peptic Ulcer*
Proton Pump Inhibitors
Proton Pumps
Recurrence
Risk Factors
Smoking
Stress, Psychological
Ulcer
Proton Pump Inhibitors
Proton Pumps

Reference

References

1. Peterson WL, Ciociola AA, Sykes DL, McSorley DJ, Webb DD. Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing ulcer recurrence. RBC H. pylori Study Group. Aliment Pharmacol Ther. 1996; 10:251–261.

2. Jyotheeswaran S, Shah AN, Jin HO, Potter GD, Ona FV, Chey WY. Prevalence of Helicobacter pylori in peptic ulcer patients in greater Rochester, NY: is empirical triple therapy justified? Am J Gastroenterol. 1998; 93:574–578.

3. Ciociola AA, McSorley DJ, Turner K, Sykes D, Palmer JB. Helicobacter pylori infection rates in duodenal ulcer patients in the United States may be lower than previously estimated. Am J Gastroenterol. 1999; 94:1834–1840.

4. Arroyo MT, Forne M, de Argila CM, et al. The prevalence of peptic ulcer not related to Helicobacter pylori or non-steroidal anti-inflammatory drug use is negligible in southern Europe. Helicobacter. 2004; 9:249–254.

5. Sbrozzi-Vanni A, Zullo A, Di Giulio E, et al. Low prevalence of idiopathic peptic ulcer disease: an Italian endoscopic survey. Dig Liver Dis. 2010; 42:773–776.

6. Musumba C, Jorgensen A, Sutton L, et al. The relative contribution of NSAIDs and Helicobacter pylori to the aetiology of endoscopically-diagnosed peptic ulcer disease: observations from a tertiary referral hospital in the UK between 2005 and 2010. Aliment Pharmacol Ther. 2012; 36:48–56.

7. Ootani H, Iwakiri R, Shimoda R, et al. Role of Helicobacter pylori infection and nonsteroidal anti-inflammatory drug use in bleeding peptic ulcers in Japan. J Gastroenterol. 2006; 41:41–46.

8. Chan HL, Wu JC, Chan FK, et al. Is non-Helicobacter pylori, non-NSAID peptic ulcer a common cause of upper GI bleeding? A prospective study of 977 patients. Gastrointest Endosc. 2001; 53:438–442.

9. Jang HJ, Choi MH, Shin WG, et al. Has peptic ulcer disease changed during the past ten years in Korea? A prospective multicenter study. Dig Dis Sci. 2008; 53:1527–1531.

10. Kang JM, Seo PJ, Kim N, et al. Analysis of direct medical care costs of peptic ulcer disease in a Korean tertiary medical center. Scand J Gastroenterol. 2012; 47:36–42.

11. Roy PK, Venzon DJ, Shojamanesh H, et al. Zollinger-Ellison syndrome. Clinical presentation in 261 patients. Medicine (Baltimore). 2000; 79:379–411.

12. Callaghan J, Brown S, Battcock T, Parry S, Snook J. Aggressive Helicobacter pylori-negative peptic ulceration as the initial manifestation of Crohn's disease. Frontline Gastroenterol. 2012; 3:201–205.

13. Uyub AM, Raj SM, Visvanathan R, et al. Helicobacter pylori infection in northeastern peninsular Malaysia. Evidence for an unusually low prevalence. Scand J Gastroenterol. 1994; 29:209–213.

14. Niv Y, Boltin D, Halpern M, et al. Membrane-bound mucins and mucin terminal glycans expression in idiopathic or Helicobacter pylori, NSAID associated peptic ulcers. World J Gastroenterol. 2014; 20:14913–14920.

15. Azuma T, Konishi J, Ito Y, et al. Genetic differences between duodenal ulcer patients who were positive or negative for Helicobacter pylori. J Clin Gastroenterol. 1995; 21(Suppl 1):S151–S154.

16. Iijima K, Kanno T, Koike T, Shimosegawa T. Helicobacter pylori-negative, non-steroidal anti-inflammatory drug: negative idiopathic ulcers in Asia. World J Gastroenterol. 2014; 20:706–713.

17. Hung LC, Ching JY, Sung JJ, et al. Longterm outcome of Helicobacter pylori-negative idiopathic bleeding ulcers: a prospective cohort study. Gastroenterology. 2005; 128:1845–1850.

18. Wong GL, Wong VW, Chan Y, et al. High incidence of mortality and recurrent bleeding in patients with Helicobacter pylori-negative idiopathic bleeding ulcers. Gastroenterology. 2009; 137:525–531.

19. Chung WC, Jeon EJ, Kim DB, et al. Clinical characteristics of Helicobacter pylori-negative drug-negative peptic ulcer bleeding. World J Gastroenterol. 2015; 21:8636–8643.

20. Wong GL, Au KW, Lo AO, et al. Gastroprotective therapy does not improve outcomes of patients with Helicobacter pylori-negative idiopathic bleeding ulcers. Clin Gastroenterol Hepatol. 2012; 10:1124–1129.